Tumor-Targeted Erythrocyte Membrane Nanoparticles for Theranostics of Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) cells do not contain various receptors for targeted treatment, a reason behind the poor prognosis of this disease. In this study, biocompatible theranostic erythrocyte-derived nanoparticles (EDNs) were developed and evaluated for effective early diagnosis and tre...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutics 2023-01, Vol.15 (2), p.350
Main Authors: Choi, Moon Jung, Lee, Yeon Kyung, Choi, Kang Chan, Lee, Do Hyun, Jeong, Hwa Yeon, Kang, Seong Jae, Kim, Min Woo, You, Young Myoung, Im, Chan Su, Lee, Tae Sup, Park, Yong Serk
Format: Article
Language:English
Subjects:
Antibodies
Breast cancer
Carbon dioxide
Dosage and administration
Doxorubicin
drug delivery system
Drug delivery systems
Drugs
Epidermal growth factor
erythrocyte-derived nanoparticle
Erythrocytes
Evaluation
Health aspects
Lipids
Materials
Membranes
Nanoparticles
Proteins
Quantum dots
triple-negative breast cancer
tumor-targeted therapy
Vehicles
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Triple-negative breast cancer (TNBC) cells do not contain various receptors for targeted treatment, a reason behind the poor prognosis of this disease. In this study, biocompatible theranostic erythrocyte-derived nanoparticles (EDNs) were developed and evaluated for effective early diagnosis and treatment of TNBC. The anti-cancer drug, doxorubicin (DOX), was encapsulated into the EDNs and diagnostic quantum dots (QDs) were incorporated into the lipid bilayers of EDNs for tumor bio-imaging. Then, anti-epidermal growth factor receptor (EGFR) antibody molecules were conjugated to the surface of EDNs for TNBC targeting (iEDNs). According to the confocal microscopic analyses and biodistribution assay, iEDNs showed a higher accumulation in EGFR-positive MDA-MB-231 cancers in vitro as well as in vivo, compared to untargeted EDNs. iEDNs containing doxorubicin (iEDNs-DOX) showed a stronger inhibition of target tumor growth than untargeted ones. The resulting anti-EGFR iEDNs exhibited strong biocompatibility, prolonged blood circulation, and efficient targeting of TNBC in mice. Therefore, iEDNs may be used as potential TNBC-targeted co-delivery systems for therapeutics and diagnostics.
ISSN:1999-4923
1999-4923
DOI:10.3390/pharmaceutics15020350